4.73
0.70 (17.37%)
Penutupan Terdahulu | 4.03 |
Buka | 4.58 |
Jumlah Dagangan | 530,778 |
Purata Dagangan (3B) | 127,511 |
Modal Pasaran | 1,679,656,192 |
Harga / Pendapatan (P/E Ke hadapan) | 59.88 |
Harga / Jualan (P/S) | 1.68 |
Harga / Buku (P/B) | 1.41 |
Julat 52 Minggu | |
Tarikh Pendapatan | 13 Aug 2025 |
Margin Keuntungan | -24.60% |
Margin Operasi (TTM) | 0.53% |
EPS Cair (TTM) | -0.630 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 9.90% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 46.13% |
Nisbah Semasa (MRQ) | 1.98 |
Aliran Tunai Operasi (OCF TTM) | 18.22 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -85.91 M |
Pulangan Atas Aset (ROA TTM) | -2.37% |
Pulangan Atas Ekuiti (ROE TTM) | -18.92% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
Stok | Evotec SE | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | -0.50 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
Sektor | Healthcare |
Industri | Drug Manufacturers - Specialty & Generic |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Institusi | 2.51% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Dcf Advisers, Llc | 31 Mar 2025 | 751,579 |
Lighthouse Investment Partners, Llc | 31 Mar 2025 | 37,545 |
Fore Capital, Llc | 31 Mar 2025 | 17,005 |
Quadrant Capital Group Llc | 31 Mar 2025 | 5,300 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
07 May 2025 | Pengumuman | Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments |
06 May 2025 | Pengumuman | Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment |
29 Apr 2025 | Pengumuman | Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025 |
24 Apr 2025 | Pengumuman | Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb |
17 Apr 2025 | Pengumuman | Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results |
10 Apr 2025 | Pengumuman | Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 |
04 Mar 2025 | Pengumuman | Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |